Neutralizing Th2 inflammation in neonatal islets prevents β-cell failure in adult IUGR rats
- Lane J. Jaeckle Santos1,2,
- Changhong Li1,2,
- Paschalis-Thomas Doulias2,
- Harry Ischiropoulos1,2,
- G. Scott Worthen1,2⇑ and
- Rebecca A. Simmons1,2⇑
- 1Perelman School of Medicine at University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA
- 2Children's Hospital of Philadelphia, 3516 Civic Center Boulevard, Philadelphia, PA 19104, USA
- Corresponding Author: Rebecca A. Simmons, ( ), G. Scott Worthen, ( )
Intrauterine growth restriction (IUGR) leads to development of type 2 diabetes (T2D) in adulthood. The mechanisms underlying this phenomenon have not been fully elucidated. Inflammation is associated with T2D, however, it is unknown whether inflammation is causal or secondary to the altered metabolic state. Here we show that the mechanism by which IUGR leads to the development of T2D in adulthood is via transient recruitment of T-helper 2 (Th2) lymphocytes and macrophages in fetal islets resulting in localized inflammation. Although this immune response is short-lived, it results in a permanent reduction in islet vascularity and impaired insulin secretion. Neutralizing IL-4 antibody therapy given only in the newborn period ameliorates inflammation and restores vascularity and β-cell function into adulthood, demonstrating a novel role for Th2 immune responses in the induction and progression of T2D. In the neonatal stage, inflammation and vascular changes are reversible, and may define an important developmental window for therapeutic intervention to prevent adult onset diabetes.
- Received August 9, 2013.
- Accepted December 23, 2013.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.